Zuckerman M J, Watts M T, Bhatt B D, Ho H
Department of Medicine, Texas Tech University Health Sciences Center, El Paso 79905.
Dig Dis Sci. 1993 Sep;38(9):1651-7. doi: 10.1007/BF01303174.
Orally administered [51Cr]EDTA was used to measure intestinal permeability in subjects with infectious diarrhea and in those without gastrointestinal complaints. [51Cr]EDTA was given to 87 subjects: 63 controls (32 normal controls, and 31 disease controls), and 24 patients with infectious diarrhea. Approximately 100 microCi of [51Cr]EDTA was given orally after an overnight fast. Urine was collected for the following 24 hr. Intestinal permeability to [51Cr]EDTA in both normal volunteers and in patients with a variety of diseases not associated with intestinal injury was low and results were in a relatively narrow range. Mean 24-hr urinary excretion of [51Cr]EDTA, calculated as a percent of the administered dose, in controls was 1.6% (0.2-3.5%). Patients with infectious diarrhea associated with invasive pathogens and/or intestinal inflammation had increased excretion of [51Cr]EDTA (mean 6.1%, P < 0.0001), with elevated excretions in 75%. These results demonstrate that intestinal infections must be considered as possible causes for increased intestinal permeability as assessed by the [51Cr]EDTA test.
口服[51Cr]乙二胺四乙酸（EDTA）用于测量感染性腹泻患者以及无胃肠道不适者的肠道通透性。87名受试者接受了[51Cr]EDTA：63名对照者（32名正常对照者和31名疾病对照者），以及24名感染性腹泻患者。禁食过夜后口服约100微居里的[51Cr]EDTA。在接下来的24小时收集尿液。正常志愿者以及患有各种与肠道损伤无关疾病的患者对[51Cr]EDTA的肠道通透性较低，结果处于相对较窄的范围内。以给药剂量的百分比计算，对照者24小时尿中[51Cr]EDTA的平均排泄量为1.6%（0.2 - 3.5%）。与侵袭性病原体和/或肠道炎症相关的感染性腹泻患者[51Cr]EDTA的排泄量增加（平均6.1%，P < 0.0001），75%的患者排泄量升高。这些结果表明，肠道感染必须被视为通过[51Cr]EDTA试验评估的肠道通透性增加的可能原因。
